These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 21833668)

  • 1. Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer.
    Kong SY; Han MH; Yoo HJ; Hwang JH; Lim MC; Seo SS; Yoo CW; Kim JH; Park SY; Kang S
    Ann Surg Oncol; 2012 May; 19(5):1707-12. PubMed ID: 21833668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer.
    Paek J; Lee SH; Yim GW; Lee M; Kim YJ; Nam EJ; Kim SW; Kim YT
    Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):338-42. PubMed ID: 21683503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
    Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients.
    Steffensen KD; Waldstrøm M; Brandslund I; Petzold M; Jakobsen A
    Int J Gynecol Cancer; 2012 Nov; 22(9):1474-82. PubMed ID: 23095772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.
    Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
    Int J Gynecol Cancer; 2011 Aug; 21(6):1040-7. PubMed ID: 21738039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Carpén O; Matomäki J; Oksa S; Virtanen J; Grénman S
    Tumour Biol; 2014 Dec; 35(12):12389-95. PubMed ID: 25190018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
    Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
    Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of serum human epididymis protein 4 in epithelial ovarian cancer and its correlation with prognosis].
    Zheng H; Gao YN; Gao WJ; Gao M; Yan X
    Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):445-9. PubMed ID: 24119905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
    Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
    Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer.
    Aarenstrup Karlsen M; Høgdall C; Nedergaard L; Philipsen Prahm K; Schou Karlsen NM; Weng Ekmann-Gade A; Henrichsen Schnack T; Svenstrup Poulsen T; Jarle Christensen I; Høgdall E
    APMIS; 2016 Dec; 124(12):1038-1045. PubMed ID: 27859687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y; Li L
    Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer.
    Plotti F; Scaletta G; Capriglione S; Montera R; Luvero D; Lopez S; Gatti A; De Cicco Nardone C; Terranova C; Angioli R
    Int J Gynecol Cancer; 2017 May; 27(4):696-702. PubMed ID: 28406844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum HE4 Profile During Primary Chemotherapy of Epithelial Ovarian Cancer.
    Hynninen J; Auranen A; Dean K; Lavonius M; Carpen O; Perheentupa A; Seppänen M; Grénman S
    Int J Gynecol Cancer; 2011 Dec; 21(9):1573-8. PubMed ID: 21811175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer.
    Mathey S; Graeser MK; Zu Eulenburg C; Woelber L; Trillsch F; Jaenicke F; Müller V; Milde-Langosch K; Mahner S
    Oncology; 2013; 85(2):69-77. PubMed ID: 23860180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.
    Karlsen MA; Fagö-Olsen C; Høgdall E; Schnack TH; Christensen IJ; Nedergaard L; Lundvall L; Lydolph MC; Engelholm SA; Høgdall C
    Tumour Biol; 2016 Sep; 37(9):12619-12626. PubMed ID: 27440204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience.
    Bamias A; Karadimou A; Soupos N; Sotiropoulou M; Zagouri F; Haidopoulos D; Thomakos N; Rodolakis A; Antsaklis A; Dimopoulos MA
    Gynecol Oncol; 2011 Oct; 123(1):37-42. PubMed ID: 21764430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
    Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
    Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
    Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
    Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer.
    Lee S; Choi S; Lee Y; Chung D; Hong S; Park N
    J Obstet Gynaecol Res; 2017 Jan; 43(1):220-227. PubMed ID: 27862665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.